Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

Documenti analoghi

• Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.
  di: Yusuf Ziya Sener, et al.
  Pubblicazione: (2025)
• Key Points in the Association of Rheumatoid Arthritis With Major Adverse Cardiovascular Events and Malignancies
  di: Seher Sener, et al.
  Pubblicazione: (2025)
• Digital twins: Unlocking comparative evidence that clinical research urgently needs
  di: Andrej Belančić, et al.
  Pubblicazione: (2025)
• Subclinical Myocardial Dysfunction in Systemic Lupus Erythematosus: The Role of Layer‐Specific Strain and Clinical Modifiers
  di: Ömer Faruk Yılmaz, et al.
  Pubblicazione: (2026)
• Closing the Evidence Gap: Retrospective and Prospective Strategies to Advance Aripiprazole's Potential Benefits in Patients With Cancer
  di: Elvira Meni Maria Gkrinia, et al.
  Pubblicazione: (2025)